Generation of broad cytotoxic T-lymphocyte responses against multiple epitopes and tumor-associated antigens (TAAs) may provide effective immunotherapy in patients with cancer. We evaluated a ...
As cancer cases continue to rise and combination therapies gain prominence, the global cytotoxic drugs market is set for ...
METUCHEN, N.J.--(BUSINESS WIRE)--Tevogen Bio, a clinical stage biotechnology company specializing in immunotherapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback